Therefore, mutant p53 aggregates may be considered a sensitive client substrate of HSP90, and targeting HSP90 might be a highly selective and efficient therapy against chemoresistance in breast cancer with mutant p53 aggregates. Here, TP53 is linked to breast cancer.